{"id":"actonel-risedronate","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Gastrointestinal irritation (esophageal irritation, dyspepsia)"},{"rate":"5-10","effect":"Musculoskeletal pain"},{"rate":"3-5","effect":"Headache"},{"rate":"<1","effect":"Atypical femoral fracture (rare)"},{"rate":"<1","effect":"Osteonecrosis of the jaw (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risedronate is a bisphosphonate that localizes to sites of bone resorption and directly inhibits osteoclast function, reducing bone turnover. By suppressing osteoclast-mediated bone resorption, it increases bone mineral density and reduces fracture risk in conditions characterized by accelerated bone loss.","oneSentence":"Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:11.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Paget's disease of bone"},{"name":"Glucocorticoid-induced osteoporosis"},{"name":"Bone metastases (supportive care)"}]},"trialDetails":[{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT04922333","phase":"PHASE3","title":"Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-28","conditions":"Bone Loss","enrollment":200},{"nctId":"NCT07009795","phase":"NA","title":"Rise & Renew: Supporting Well-Being in Black Women After the Loss of a Loved One","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lillian Haley, PhD","startDate":"2025-05-20","conditions":"Bereavement, Grief, Psychological Distress","enrollment":40},{"nctId":"NCT04152551","phase":"PHASE4","title":"Effects of Bisphosphonates on OI-Related Hearing Loss","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-11-02","conditions":"Osteogenesis Imperfecta","enrollment":100},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT05630768","phase":"PHASE4","title":"Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-01-03","conditions":"Postmenopausal Osteoporosis","enrollment":149},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT00092040","phase":"PHASE3","title":"A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03-18","conditions":"Osteoporosis, Postmenopausal","enrollment":936},{"nctId":"NCT00092014","phase":"PHASE3","title":"A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09-01","conditions":"Postmenopausal Osteoporosis","enrollment":1053},{"nctId":"NCT00567606","phase":"NA","title":"Prevention of Osteoporosis in Breast Cancer Survivors","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-04-01","conditions":"Postmenopausal Osteoporosis","enrollment":249},{"nctId":"NCT02186600","phase":"PHASE3","title":"Heartland Osteoporosis Prevention Study","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-02-01","conditions":"Osteopenia","enrollment":276},{"nctId":"NCT04879420","phase":"","title":"Replication of the VERO Osteoporosis Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-10-29","conditions":"Osteoporosis","enrollment":12757},{"nctId":"NCT03861091","phase":"PHASE2","title":"Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-07-12","conditions":"Lung Neoplasm","enrollment":84},{"nctId":"NCT05803681","phase":"NA","title":"CCEF in the Treatment of Acute VFFs: Randomized Controlled Trial","status":"COMPLETED","sponsor":"University of Bari Aldo Moro","startDate":"2015-01-01","conditions":"Vertebral Fracture, Osteoporotic Fractures","enrollment":70},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT00594334","phase":"PHASE4","title":"Effect of Actonel on Periodontal Health of Postmenopausal Women","status":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-01","conditions":"Periodontal Disease","enrollment":""},{"nctId":"NCT05346419","phase":"NA","title":"Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients","status":"COMPLETED","sponsor":"Hospital Regional 1o de Octubre","startDate":"2021-07-01","conditions":"Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism","enrollment":33},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":"Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma","enrollment":684815},{"nctId":"NCT00445575","phase":"PHASE2, PHASE3","title":"Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2007-07-22","conditions":"Fibrous Dysplasia of Bone","enrollment":80},{"nctId":"NCT01950169","phase":"NA","title":"Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2004-12","conditions":"Hip Fracture","enrollment":79},{"nctId":"NCT03411902","phase":"PHASE4","title":"Weight Loss With Risedronate for Bone Health","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06-15","conditions":"Bariatric Surgery Candidate, Bone Loss, Weight Loss","enrollment":24},{"nctId":"NCT00452439","phase":"PHASE3","title":"A Study of Actonel for the Prevention of Bone Loss","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-02","conditions":"Leukemia, Lymphoma","enrollment":72},{"nctId":"NCT00089843","phase":"PHASE2, PHASE3","title":"Bone Loss in Women With Anorexia Nervosa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-06","conditions":"Anorexia Nervosa","enrollment":77},{"nctId":"NCT00919711","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-09-01","conditions":"Osteoporosis","enrollment":870},{"nctId":"NCT01406444","phase":"NA","title":"IGF-1 and Bone Loss in Women With Anorexia Nervosa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2011-10","conditions":"Anorexia Nervosa, Osteopenia, Osteoporosis","enrollment":148},{"nctId":"NCT00354302","phase":"PHASE3","title":"Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-04-24","conditions":"Breast Cancer, Osteoporosis","enrollment":497},{"nctId":"NCT00887354","phase":"PHASE4","title":"A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-04","conditions":"Osteoporosis","enrollment":224},{"nctId":"NCT01709110","phase":"PHASE4","title":"VERtebral Fracture Treatment Comparisons in Osteoporotic Women","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Postmenopausal Osteoporosis","enrollment":1366},{"nctId":"NCT01675297","phase":"PHASE4","title":"Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2011-07-04","conditions":"Osteoporosis","enrollment":1053},{"nctId":"NCT02106442","phase":"","title":"36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-05-13","conditions":"Osteoporosis","enrollment":579},{"nctId":"NCT04034199","phase":"PHASE3","title":"Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid","status":"UNKNOWN","sponsor":"Kwong Wah Hospital","startDate":"2019-08-15","conditions":"Idiopathic Inflammatory Myopathies, Osteoporosis, Osteopenia","enrollment":40},{"nctId":"NCT02106455","phase":"","title":"Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08-01","conditions":"Osseous Paget's Disease","enrollment":315},{"nctId":"NCT00266708","phase":"PHASE1, PHASE2","title":"Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2002-10","conditions":"Renal Transplant Osteodystrophy","enrollment":60},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":"Postmenopausal Osteoporosis","enrollment":86},{"nctId":"NCT02731040","phase":"","title":"Exome Sequencing for Atypical Femoral Fractures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":"Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy","enrollment":38},{"nctId":"NCT02089997","phase":"","title":"Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-05-27","conditions":"Osteoporosis","enrollment":3304},{"nctId":"NCT02744482","phase":"PHASE3","title":"Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis","status":"TERMINATED","sponsor":"University Hospital, Limoges","startDate":"2016-05","conditions":"Prosthesis Loosening","enrollment":3},{"nctId":"NCT03208582","phase":"PHASE2","title":"Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?","status":"COMPLETED","sponsor":"Sheffield Children's NHS Foundation Trust","startDate":"2017-04-01","conditions":"Osteogenesis Imperfecta","enrollment":13},{"nctId":"NCT01904110","phase":"PHASE4","title":"To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Osteoporosis","enrollment":196},{"nctId":"NCT01575873","phase":"PHASE3","title":"Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-28","conditions":"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor","enrollment":795},{"nctId":"NCT00405392","phase":"PHASE4","title":"Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-22","conditions":"Osteoporosis, Postmenopausal","enrollment":365},{"nctId":"NCT00244907","phase":"PHASE1","title":"Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women","status":"COMPLETED","sponsor":"Purdue University","startDate":"2006-01","conditions":"Osteoporosis, Osteopenia","enrollment":23},{"nctId":"NCT00859027","phase":"PHASE4","title":"Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer","status":"COMPLETED","sponsor":"UConn Health","startDate":"2003-01","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT00666627","phase":"PHASE2","title":"Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-04","conditions":"Post-menopausal Osteoporosis","enrollment":410},{"nctId":"NCT00232466","phase":"NA","title":"VERTOS-II. Percutaneous Vertebroplasty Versus Conservative Therapy","status":"COMPLETED","sponsor":"Clinical Research Office Imaging Division","startDate":"2006-02","conditions":"Osteoporosis, Back Pain","enrollment":200},{"nctId":"NCT01882400","phase":"PHASE4","title":"Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy","status":"COMPLETED","sponsor":"Gilles Boire","startDate":"2001-05","conditions":"Osteoporosis, Muscular Dystrophy, Cystic Fibrosis","enrollment":11},{"nctId":"NCT00485953","phase":"PHASE4","title":"Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Susan L. Greenspan","startDate":"2007-09","conditions":"Bone Loss, Osteoporosis, Breast Cancer","enrollment":109},{"nctId":"NCT01038011","phase":"PHASE2","title":"Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2004-06","conditions":"Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT02063854","phase":"PHASE2, PHASE3","title":"A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Involutional Osteoporosis","enrollment":871},{"nctId":"NCT00043069","phase":"PHASE3","title":"Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-11","conditions":"Osteoporosis, Prostate Cancer","enrollment":71},{"nctId":"NCT02148848","phase":"PHASE4","title":"Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2013-06","conditions":"Osteoporotic Fractures, Femoral Neck Fracture","enrollment":86},{"nctId":"NCT00377234","phase":"PHASE4","title":"A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Post Menopausal Osteoporosis","enrollment":356},{"nctId":"NCT00054418","phase":"PHASE3","title":"Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-03","conditions":"Breast Cancer, Osteoporosis","enrollment":216},{"nctId":"NCT00216060","phase":"PHASE3","title":"Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy","status":"TERMINATED","sponsor":"Christopher Sweeney, MBBS","startDate":"2003-10","conditions":"Metastatic Prostate Cancer","enrollment":63},{"nctId":"NCT00118508","phase":"NA","title":"The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-05","conditions":"Osteoporosis","enrollment":87},{"nctId":"NCT00869622","phase":"PHASE4","title":"Antiepileptic Drugs and Osteoporotic Prevention Trial","status":"COMPLETED","sponsor":"Boston VA Research Institute, Inc.","startDate":"2006-06","conditions":"Epilepsy, Bone Loss, Osteoporosis","enrollment":80},{"nctId":"NCT00918749","phase":"PHASE2","title":"Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-05","conditions":"Postmenopausal Osteoporosis","enrollment":205},{"nctId":"NCT00221299","phase":"PHASE4","title":"Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-09","conditions":"Osteoporosis","enrollment":60},{"nctId":"NCT00772395","phase":"PHASE4","title":"Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Danderyd Hospital","startDate":"2006-04","conditions":"Bone Loss","enrollment":78},{"nctId":"NCT01611571","phase":"PHASE3","title":"Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis","status":"COMPLETED","sponsor":"Columbia University","startDate":"2003-12","conditions":"Osteoporosis","enrollment":31},{"nctId":"NCT00859703","phase":"PHASE3","title":"Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-11","conditions":"Breast Cancer, Menopause, Osteopenia","enrollment":20},{"nctId":"NCT00837746","phase":"","title":"Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2003-04","conditions":"Osteoporosis","enrollment":29},{"nctId":"NCT00778154","phase":"","title":"Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-01","conditions":"Postmenopausal Osteoporosis","enrollment":105},{"nctId":"NCT00106028","phase":"PHASE3","title":"Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-11","conditions":"Osteogenesis Imperfecta","enrollment":143},{"nctId":"NCT00247273","phase":"PHASE3","title":"A Study of Monthly Risedronate for Osteoporosis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2005-10","conditions":"Postmenopausal Osteoporosis","enrollment":1294},{"nctId":"NCT00541658","phase":"PHASE3","title":"A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-10","conditions":"Postmenopausal Osteoporosis","enrollment":923},{"nctId":"NCT00577395","phase":"PHASE4","title":"Bone Microarchitecture in Osteopenic Postmenopausal Women","status":"TERMINATED","sponsor":"Warner Chilcott","startDate":"2008-07","conditions":"Osteoporosis","enrollment":13},{"nctId":"NCT00577837","phase":"PHASE2","title":"Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-04","conditions":"Postmenopausal","enrollment":370},{"nctId":"NCT00577850","phase":"PHASE1","title":"Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2002-11","conditions":"Osteopenia, Osteoporosis","enrollment":32},{"nctId":"NCT00699777","phase":"PHASE1","title":"Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2008-01","conditions":"Osteoporosis","enrollment":96},{"nctId":"NCT00145704","phase":"NA","title":"Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density","status":"TERMINATED","sponsor":"State University of New York - Upstate Medical University","startDate":"2002-06","conditions":"Osteopenia","enrollment":6},{"nctId":"NCT01806792","phase":"PHASE3","title":"Post-menopausal Women Osteoporosis(Phase III)","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2009-11","conditions":"Postmenopausal Women Osteoporosis","enrollment":150},{"nctId":"NCT00324714","phase":"PHASE3","title":"Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS","status":"WITHDRAWN","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-02","conditions":"Breast Cancer, Osteoporosis","enrollment":""},{"nctId":"NCT00365456","phase":"PHASE3","title":"Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-07","conditions":"Osteoporosis","enrollment":407},{"nctId":"NCT00447915","phase":"PHASE3","title":"Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-03","conditions":"Primary Osteoporosis","enrollment":1265},{"nctId":"NCT00103740","phase":"PHASE3","title":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-04","conditions":"Paget's Disease of Bone","enrollment":185},{"nctId":"NCT00051636","phase":"PHASE3","title":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2001-01","conditions":"Paget's Disease of Bone","enrollment":172},{"nctId":"NCT00503399","phase":"PHASE3","title":"Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-07","conditions":"Osteoporosis","enrollment":92},{"nctId":"NCT00351091","phase":"PHASE2","title":"Risedronate in Postmenopausal Women With Low Bone Density","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-11","conditions":"OSTEOPOROSIS, POSTMENOPAUSAL","enrollment":150},{"nctId":"NCT00426777","phase":"PHASE3","title":"Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer","status":"COMPLETED","sponsor":"CMX Research","startDate":"2007-01","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT00577720","phase":"PHASE2","title":"Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-07","conditions":"Postmenopausal Women","enrollment":181},{"nctId":"NCT00386360","phase":"PHASE3","title":"Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-04","conditions":"Osteopenia","enrollment":161},{"nctId":"NCT00136058","phase":"PHASE3","title":"Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2002-01","conditions":"Osteoporosis","enrollment":250},{"nctId":"NCT01249261","phase":"PHASE3","title":"Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2001-10","conditions":"Postmenopausal Women With Osteoporosis","enrollment":61},{"nctId":"NCT00619957","phase":"PHASE3","title":"Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2002-06","conditions":"Other Osteoporosis","enrollment":285},{"nctId":"NCT00755872","phase":"PHASE1","title":"Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-11","conditions":"Bioavailability","enrollment":76},{"nctId":"NCT00717145","phase":"PHASE1","title":"Food Effects on the Relative Bioavailability of Different Dosages of Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2008-07","conditions":"Postmenopausal, Non-lactating, Surgically Sterile","enrollment":94},{"nctId":"NCT00868907","phase":"PHASE1","title":"Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-03","conditions":"Healthy","enrollment":101},{"nctId":"NCT00846196","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-01","conditions":"Osteoporosis","enrollment":538},{"nctId":"NCT00460733","phase":"PHASE4","title":"SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Colles' Fracture","enrollment":141},{"nctId":"NCT00577421","phase":"PHASE3","title":"Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2003-06","conditions":"Postmenopausal Osteoporosis","enrollment":32},{"nctId":"NCT00343252","phase":"PHASE3","title":"Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-06","conditions":"Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture","enrollment":712},{"nctId":"NCT00082277","phase":"PHASE4","title":"Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Breast Cancer","enrollment":237},{"nctId":"NCT00130403","phase":"PHASE4","title":"OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-03","conditions":"Osteoporosis, Postmenopausal","enrollment":290},{"nctId":"NCT00268632","phase":"PHASE3","title":"IMPACT Study (Improving Measurements of Persistence on \"ACtonel\" Treatment)","status":"COMPLETED","sponsor":"Sanofi","startDate":"1999-08","conditions":"Osteoporosis","enrollment":""},{"nctId":"NCT00790101","phase":"PHASE4","title":"Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2004-06","conditions":"Osteoporosis, Postmenopausal","enrollment":6},{"nctId":"NCT00138866","phase":"PHASE3","title":"Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury","status":"COMPLETED","sponsor":"Toronto Rehabilitation Institute","startDate":"2004-11","conditions":"Osteoporosis","enrollment":46},{"nctId":"NCT01215890","phase":"PHASE4","title":"Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease","status":"COMPLETED","sponsor":"University of Alberta","startDate":"","conditions":"Crohn's Disease, Low Bone Mineral Density","enrollment":""},{"nctId":"NCT00353080","phase":"PHASE3","title":"Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-12","conditions":"Osteoporosis, Postmenopausal","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2009,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Risedronate Sodium","Actonel"],"phase":"phase_3","status":"active","brandName":"Actonel (Risedronate)","genericName":"Actonel (Risedronate)","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity. Used for Osteoporosis in postmenopausal women, Paget's disease of bone, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}